AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00515021
Drug: Eplerenone (Morning)
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eplerenone - 50mg, by mouth, daily, in the morning x 2 weeks followed by 4 weeks at 100mg.~100mg, by mouth, daily, in the morning x 4 weeks then patients cross over to 100mg, by mouth, daily, in the evening x another 4 weeks.
Trial: NCT00515021
Drug: Eplerenone (Night-time)
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eplerenone - 50mg, by mouth, daily in the evening x 2 weeks followed by 4 weeks at 100mg
Trial: NCT01446159
Drug: MEDI-573
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of MEDI-573 (10 or 30 or 45 mg/kg) will be administered on Day 1 of each 21-day cycle until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
Trial: NCT01446159
Drug: Aromatase Inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aromatase inhibitor of the investigator's choice (letrozole, anastrozole, or exemestane) will be provided orally once daily until unacceptable toxicity, documentation of disease progression, or withdrawal for other reasons.
Trial: NCT03710187
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Hydrocortisone 50 mg IV Q6h
Trial: NCT00298012
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00627393
Drug: Standard antimicrobial therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antimicrobial therapy is broadly defined as therapy within the standard of care for a particular infection and should be consistent within a given institution. Participants will undergo the recommended therapy for specific infections for 42 days.
Trial: NCT03337308
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet or capsule to match bempedoic acid + ezetimibe fixed-dose combination (FDC) 180 mg/10 mg tablet, or bempedoic acid 180 mg tablet, or ezetimibe 10 mg capsule
Trial: NCT01794429
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneum injection of placebo once-weekly for 3 months
Trial: NCT01066637
Drug: [18F](+/-)NOS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection of radiotracer \[18F\](+/-)NOS for PET imaging and kinetic data analysis
Trial: NCT03527927
Drug: Any LABA/LAMA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Following consent, patients will be taken off their current ICS/LABA/LAMA combination inhalers and shown 4 single inhaler LABA/LAMA devices and asked to choose a preferred device to use, provided they can demonstrate effective use.
Trial: NCT00397527
Drug: lactoserum
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00171964
Drug: Zoledronic acid in combination with therapy
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT00182364
Drug: Fragmin (Dalteparin) LMWH verus Unfractionated Heparin (UFH)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03210558
Drug: Testosterone cream 1% (Andro-Feme® )
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone cream 10 mg (1 ml) daily, supplied every evening via a dose applicator to the upper outer thigh for 10 weeks.
Trial: NCT03210558
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream (1 ml) daily, supplied every evening via a dose applicator to the upper outer thigh for 10 weeks.
Trial: NCT02246530
Drug: Subacromial steroid bursal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination steroid (Celestone) and anesthetic drug (Lidocaine) will be injected into the patient's subacromial bursa via needle guidance of ultrasound
Trial: NCT01906489
Drug: AKB-6548
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral dose administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
Trial: NCT01906489
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Placebo administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
Trial: NCT00236223
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT04094285
Drug: SAUERSTOFF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAUERSTOFF medizinisch, Messer GmbH, Industriestrasse 5, 2352 Gumpoldskirchen, Austria~Dose:~min. 95.5%, breathing for 30 minutes
Trial: NCT02129192
Drug: T80/H12.5 mg FDC tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg FDC tablet
Trial: NCT02129192
Drug: T80/A5/H12.5 mg FDC tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg FDC tablet
Trial: NCT03433651
Drug: Creatine monohydrate
RxNorm normalized name: Creatine Monohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take by mouth 5 grams a day of creatine monohydrate powder.
Trial: NCT03433651
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take by mouth 5 grams a day of placebo powder.
Trial: NCT00788801
Drug: ABT-614
RxNorm normalized name: ABT-925
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline PET scan with radiotracer only, PET scan with radiotracer and ABT-614 Low Dose or ABT-614 High Dose
Trial: NCT00005800
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04678895
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone matched placebo capsule.
Trial: NCT03006276
Drug: DFN-15 Active
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00495274
Drug: Formulation A
RxNorm normalized name: meningococcal vaccine of unknown formulation and unknown serogroups
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation A represents the original formulation. SB-649868 10 mg film coated tablet (3 tablets to reach 30 mg), containing micronized drug substance. Formulation A will be administered in Part A.
Trial: NCT00495274
Drug: Formulation B
RxNorm normalized name: Hep B, unspecified formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation B will represent SB-649868 10 mg film coated tablet containing micronized drug substance (3 tablets to reach 30 mg), but contains additional surfactant. Formulation B will be administered in Part A.
Trial: NCT00495274
Drug: Formulation D
RxNorm normalized name: Complete Formulation D3000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation D will represent SB-649868 10 mg film coated tablet (3 tablets to reach 30 mg), containing nanomilled and spray dried powder. Formulation D will be administered in Part A.
Trial: NCT00495274
Drug: Formulation G
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formulation G will be the selected formulation of SB-649868 30 mg to be assessed in Part B. The formulation will be administered after a standard FDA High-Fat breakfast
Trial: NCT00412360
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 60 mg/kg/day will be administered as a 2 hour intravenous infusion with a high volume fluid flush on Days -3 and -2.
Trial: NCT01897779
Drug: RPX7009
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation in cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
Trial: NCT01897779
Drug: RPX2014
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation for cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
Trial: NCT01897779
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation for cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
Trial: NCT04627233
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo group received normal saline in a same volume to match corresponding HEP-1 doses. Study drug was administered by qualified staff in research clinic settings; injections were given to abdominal sites on rotating basis, by anatomic quadrant.
Trial: NCT01302340
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active treatment consists of THC in tablet form. Patients receive 0.75 mg THC twice daily during the first three treatment blocks (period A) and 1.5 mg THC twice daily during the latter three treatment blocks (period B). Placebo treatment consists of two tablets daily and is matched to the active treatment for taste, color and size. Study medication will be administered at 10 a.m. and 4 p.m., by the primary caregiver. These time points are chosen because NPS often occur later on the day, when fatigue and external signals build up to the stress and result in NPS. The order of administration of THC and placebo (1:1) will be determined by randomization per block: THC followed by placebo or placebo followed by THC.
Trial: NCT02253173
Drug: Estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02253173
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04364867
Drug: Pain Pump
RxNorm normalized name: Dermoplast Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will receive an interscalene block with Ropivicaine 0.5% (20cc), and then a pain pump attached in the Post Anesthesia Care Unit infusing at 4cc/hr. The patient will go home with that device until it runs out.
Trial: NCT01513460
Drug: NVA237 50µg once daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NVA237 50 μg o.d., delivered via single-dose dry-powder inhaler (SDDPI)
Trial: NCT01513460
Drug: Flu/Sal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device
Trial: NCT00195702
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administered, subcutaneous injection of placebo (1.6 mL/injection) once weekly (ew) for up to 52 weeks.
Trial: NCT00277823
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00832663
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: receive placebo
Trial: NCT00626106
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered with either exemestane or fulvestrant
Trial: NCT04084444
Drug: T8 tablet 0.5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune regulation, inhibition of acute nonspecific inflammation and chronic inflammation.
Trial: NCT04084444
Drug: T8 tablet 1mg
RxNorm normalized name: T8 Keto Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune regulation, inhibition of acute nonspecific inflammation and chronic inflammation.
Trial: NCT04084444
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blank control.
Trial: NCT02937272
Drug: LY3200882
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT02937272
Drug: LY3300054
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered intravenously
Trial: NCT01986166
Drug: MEHD7945A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MEHD7945A will be administered as IV infusion at a dose of 1100 mg q2w until disease progression or unacceptable toxicity.
Trial: NCT00740116
Drug: 0.9% NaCl solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl solution; 0.15 ml/kg body weight added to 100 ml 0.9% NaCl solution. The volume is given intravenously immediate before skin incision at surgery.
Trial: NCT00833872
Drug: LEO 22811
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: First-in-man
Trial: NCT00833872
Drug: placebo solution
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02581215
Drug: mFOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFIRINOX:~* Oxaliplatin 85 mg/m2 over 2-4 hours~* Irinotecan 165 mg/m2 over 90 minutes~* 5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia.
Trial: NCT02241460
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: During the Double-Blind Treatment Period, patients randomized to placebo will receive three cycles of Promescent. The first and second cycle consists of three weeks of treatment using 30 mg and 50 mg, followed by one week of washout. The third cycle consists of three weeks of treatment using 70 mg. During the Open-Label Treatment Period, the patient will receive four weeks of Promescent (active treatment) in one-week cycles: 30 mg, 50 mg, 70 mg, and patient's self-selected dose.
Trial: NCT01567072
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment with Ibuprofen 600mg 3times a day in 7 days after Colles fracture diagnosis
Trial: NCT01567072
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Treatment with Ibuprofen 600mg 3 times daily in 3 days after´diagnosis - Colles fracture
Trial: NCT01567072
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Only placebo treatment instead of NSAID painkillers
Trial: NCT01493024
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Randomized to mimic escalating doses of experimental drug administered 3 times daily (tid) with meals.
Trial: NCT03942029
Drug: LY3154207 Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally as capsule
Trial: NCT03942029
Drug: LY3154207 Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally as tablet
Trial: NCT03942029
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally as tablet
Trial: NCT04115020
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo oral suspension
Trial: NCT01432236
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo capsules twice a day for 14 weeks
Trial: NCT00214695
Drug: Experimental Peritoneal Dialysis Solution
RxNorm normalized name: DEXTROSE/PERITONEAL DIALYSIS SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01659437
Drug: Streptomycin intramuscular injection
RxNorm normalized name: streptomycin Injection
DrugBank: Streptomycin (DB01082)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: daily intramuscular drug injection
Trial: NCT01730768
Drug: AQW051
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01730768
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04094662
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo tablets for oral administration
Trial: NCT00104429
Drug: GW873140
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01823991
Drug: VitaBlue™
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self administration of nutritional supplement COGNUTRIN for 3 months.~The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza.
Trial: NCT01823991
Drug: Lovaza®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self administration of nutritional supplement COGNUTRIN for 3 months.~The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza.
Trial: NCT03263767
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 14 mg/kg intravenous 2 days at Day - 6 and day -5
Trial: NCT03263767
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg/kg intravenous 2 days at day +3 and day +4
Trial: NCT03263767
Drug: Thymoglobulin Injectable Product
RxNorm normalized name: Thymoglobulin Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: At day -2 2.5 mg/kg for patients inclued after 14 dec 2020
Trial: NCT04422652
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double-blind placebo.
Trial: NCT00551200
Drug: HPN-100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be taking prescribed dose of Buphenyl® TID (not to exceed 20g/day) at least two weeks prior to enrollment. Subjects will take prescribed dose of Buphenyl® TID for first week of study, and then switch over to HPN-100 TID during a dose-escalation phase. The dose of HPN-100 will be increased and the dose of Buphenyl® will be decreased each week by 50 mg/kg until entire daily dose of phenylbutyrate is HPN-100. Target HPN-100 dose will contain the same amount of phenylbutyrate as the subject's prescribed daily dose of Buphenyl®. Subject will take HPN-100 alone for one week and then switch back to previous dose of Buphenyl for the last week of the study.
Trial: NCT00551200
Drug: BUPHENYL®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BUPHENYL® (sodium phenylbutyrate) tablets and powder have been approved for marketing in the United States since 1996 as an adjunctive therapy in the long-term management of patients with UCDs involving deficiencies of CPS, OTC, or ASS.
Trial: NCT03641417
Drug: GLWL-01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small molecule inhibitor of Ghrelin-O-Acyltransferase (GOAT) to reduce levels of circulating acyl ghrelin.~(Defined as a mechanistic study by MHRA; intervention not for therapeutic purposes in this study.)
Trial: NCT03322540
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo administered orally twice daily.
Trial: NCT02408016
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT01544296
Drug: KHK6188
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03466528
Drug: Pabrinex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard treatment
Trial: NCT00867594
Drug: ORMD 0801
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 capsule ORMD 0801 3 times a day, before each meal
Trial: NCT01544296
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02558959
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01782898
Drug: Placebo Comparator: .9 normal saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Comparator: Placebo .9 normal saline infused at the same rate (/mg/kg bolus followed by 5-15 mcg/kg/mn) as the Esmolol would be administered,
Trial: NCT04879030
Drug: Beta-Lactams
RxNorm normalized name: BETA-LACTAMS ANTIMICROBIALS,OTHER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient was randomized to use beta-lactams antibiotic
Trial: NCT04879030
Drug: Fluoroquinolone
RxNorm normalized name: Fluoroquinolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient was indicated to use a combination of beta-lactams and fluoroquinolones
Trial: NCT01910285
Drug: Remifentanyl - sufentanil placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction of general anesthesia with 3 mg/kg of propofol combined with 3 µg/kg of remifentanil and 10 ml of isotonic sodium chloride for the double blind. The trachea is then intubated after waiting the time of action of each product.
Trial: NCT01910285
Drug: Sufentanil - remifentanyl placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction of general anesthesia with 3 mg/kg of propofol combined with 0.3 mg/kg of sufentanil and 25 ml of isotonic sodium chloride for the double blind. The trachea is then intubated after waiting the time of action of each product.
Trial: NCT02727803
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT02809963
Drug: Eplerenone
RxNorm normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg tablets, oral use.
Trial: NCT02809963
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg tablets, oral use
Trial: NCT03287960
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily subcutaneous injection
Trial: NCT00237146
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT03934333
Drug: BDA MDI 160/180 mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/albuterol sulfate pressurized inhalation suspension, single dose given as 2 inhalations of 80/90 mcg.
Trial: NCT00433173
Drug: testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: transdermal 7.5 g/per day for 3 months
Trial: NCT00357643
Drug: Calcium 500 mg/day and vitamin D 700 IU/day
FDA approved: no
EMA approved: no
PMDA approved: no